ArticleFrontiers in pharmacology2026
Mechanism of zedoary turmeric oil multi-components targeting S100A14 to reprogram astrocytes against tumor brain metastasis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zedoary Turmeric Oil (ZTO) is an active extract derived from the traditional Chinese medicine Ezhu, which is conventionally used to promote blood circulation, remove blood stasis, and relieve pain. Nevertheless, the therapeutic potential and underlying molecular mechanism of ZTO against tumor brain metastasis (BrM) remain poorly elucidated. Methods: The anti-BrM efficacy of ZTO was firstly assessed through S100A14-overexpress tuomor cells intracarotid injection BrM mice model. Concurrently, GC-MS analysis, computer simulation, along with Results: Our study first identified ZTO as a promising candidate against S100A14-driven BrM. In mouse model, high-dose ZTO (200 mg/kg) significantly reduced Conclusion: ZTO exhibited potent anti-BrM efficacy and the mechanism involved multiple components synergistically targeting S100A14 to reprogram astrocytes, which in turn reduced the secretion of pro-inflammatory factors, thereby inhibiting the recruitment of MDSCs and reshaping the immunosuppressive microenvironment of the brain. Collectively, our study provides the first experimental evidence that the multiple bioactive components in ZTO act synergistically to target S100A14, offering a promising new direction for the development of anti-BrM therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.